… proven survival advantage for patients with locally advanced … phase 3b, multicenter, open-label
trial of erlotinib in patients … and safety of erlotinib monotherapy in patients with advanced …

… We designed the phase 3, placebo-controlled Sequential … use of erlotinib as maintenance
therapy in patients with non-… in the erlotinib group received no trial treatment; two patients in …

… often still received erlotinib in the second-line and … trial to directly compare the efficacy of
erlotinib with cabozantinib, and to compare erlotinib with cabozantinib plus erlotinib, in patients …

… phase 3 results confirm these early findings. Furthermore, retrospective analyses of two phase
3 NSCLC trials … correlation between rash and treatment effect on survival: the BR.21 trial …

7501 Background: The proven efficacy of E in advanced NSCLC warranted its evaluation in
the adjuvant setting. BR.21 data suggested pts with EGFR positive tumors (IHC/FISH) were …

… this trial. Our hypothesis that this subset of patients might benefit from adjuvant erlotinib was
based on data from retrospective exploratory biomarker analyses of two trials in advanced …

… compared with erlotinib was more pronounced (median 3·71 … phase 3 trial to compare
dacomitinib with erlotinib in patients with advanced non-small-cell lung cancer, including patients …

… We randomly assigned eligible patients in a 1:1 ratio to receive oral erlotinib (150 mg/day)
plus either intravenous ramucirumab (10 mg/kg) or matching placebo once every 2 weeks. …

… age 20 years or older were eligible if they met the following criteria: pathologically or
histologically proven NSCLC with stage IIIB or IV disease (International Union Against Cancer, …

… ≥18 years old with histologically or cytologically confirmed stage IIIB/… trial to our knowledge
to prospectively investigate erlotinib … results in Chinese patients in the OPTIMAL trial. These …